Sobi expands partnership with Ionis Pharmaceuticals to include olezarsen commercialisation outside the U.S.
Sobi and Ionis have entered into a license agreement under which Sobi receives exclusive rights in countries outside the U.S., Canada, and China to commercialise olezarsen as a potential treatment for familial chylomicronemia syndrome (FCS) and severely elevated triglycerides. Olezarsen is currently under review by the European Medicines Agency (EMA) with a potential approval expected for the treatment of FCS this year.
Please find a link to the announcement by our partner, Ionis.
Sobi is Ionis’ current European commercialization partner for Waylivra® (volanesorsen), the only medicine approved for FCS in Europe. This agreement builds upon our long-standing partnership with Ionis and leverages our existing market ability and distribution channels to enable an effective olezarsen launch in FCS, and potentially the broader population of people with severely elevated triglycerides, assuming approval.
About Familial Chylomicronemia Syndrome (FCS)
FCS is a rare genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. People living with FCS are at high risk of acute pancreatitis in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. FCS is thought to affect one to two people per million, and an estimated 3,000 to 5,000 people globally are thought to live with the disease.1
1.The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study - ScienceDirect
We provide access to innovative treatments that transform life for people.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present current and past media releases, images and videos.
- About
- Therapeutic areas
- Medicines
- Stories
- Sustainability
- Careers
- Investors
- Media
- English
- Swedish